NEW YORK, June 11 (Reuters) - Elan Corp on Wednesday said it resumed a mid-stage trial of its vaccine to treat Alzheimer’s disease after concerns about a potentially serious side effect in one patient were allayed by diagnostic tests.
NEW YORK, June 11 (Reuters) - Elan Corp on Wednesday said it resumed a mid-stage trial of its vaccine to treat Alzheimer’s disease after concerns about a potentially serious side effect in one patient were allayed by diagnostic tests.
